IGF-1 DES
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
IGF-1 DES — short for Des(1-3) IGF-1 — is a truncated form of insulin-like growth factor-1. It is identical to native IGF-1 except that the first three amino acids at the N-terminus (glycine, proline, and glutamate) have been removed. This truncated form also occurs naturally in the body, where proteases cleave that tripeptide from circulating IGF-1 in some tissues.
That small structural change has an outsized effect. In full-length IGF-1, most of the molecule circulates bound to IGF-binding proteins (IGFBPs), which limits how much is free to act on cells. Removing the N-terminal tripeptide sharply reduces IGFBP binding, so a larger fraction of IGF-1 DES remains bioactive.
Most of the evidence for IGF-1 DES comes from cell-culture and animal studies. Human clinical data is limited, and it is not approved by any major regulator for therapeutic use. Because of its reportedly short duration of action, it is often discussed in the context of localized, post-workout use.
How it works
IGF-1 DES signals through the type 1 IGF receptor (IGF1R), the same receptor as native IGF-1. Activation of this receptor engages anabolic pathways such as the PI3K/Akt/mTOR axis, which are involved in protein synthesis and cell growth. The distinguishing feature of the DES analog is not a different receptor but its reduced sequestration by IGF-binding proteins.
In laboratory studies, IGF-binding proteins strongly suppressed the activity of IGF-1 and IGF-2 but had little inhibitory effect on des-(1-3)-IGF-1, which helps explain why the truncated form has been reported as more potent than native IGF-1 in stimulating cell proliferation and growth-related responses. The precise behavior in humans is not well established.
Reported benefits
- Greater potency than native IGF-1 in stimulating cell growth and protein synthesis (preclinical data)
- Reduced sequestration by IGF-binding proteins, leaving more of the molecule bioactive
- Interest in localized muscle effects owing to its reportedly short duration of action
These are reported and studied effects, not guaranteed outcomes, and much of the evidence is preclinical.
Considerations & side effects
Because rigorous human trials are lacking, the safety profile of IGF-1 DES is not well characterized. As a potent growth-factor analog, the theoretical concerns most often raised relate to its effects on cell growth and to blood-sugar changes, since IGF signaling overlaps with insulin pathways; these considerations come from the broader IGF literature rather than controlled studies of this specific analog.
Product purity and identity also vary widely in the research-chemical market, and independent verification is generally not available to buyers. IGF-1 DES is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is IGF-1 DES?
A truncated version of insulin-like growth factor-1 that is missing the first three amino acids (the Gly-Pro-Glu tripeptide) from the N-terminus. This small change sharply reduces how strongly it is bound by IGF-binding proteins, which is why it is studied as a more potent, locally acting analog.
How is IGF-1 DES different from regular IGF-1?
Because it binds IGF-binding proteins far more weakly, less of it is sequestered in circulation, so in laboratory studies it has shown greater potency than native IGF-1 at stimulating cell growth and protein synthesis.
Is IGF-1 DES FDA-approved?
No. IGF-1 DES is not approved by the FDA or any major regulator for human therapeutic use, and is sold for research purposes only.
Why do users inject it near a target muscle?
It is commonly reported to have a very short duration of action, so users aim for localized rather than systemic effects. This is a reported practice, not clinical guidance.
References
- Ross M, et al. IGF-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J. 1989. ↗
- Simes JM, Wallace JC, Walton PE. Effects of IGF-I, IGF-II and des(1-3)IGF-I on growth hormone and IGF-binding protein secretion from cultured rat anterior pituitary cells. J Endocrinol. 1991. ↗
Related compounds
Potent growth hormone releasing peptide. Produces strong GH pulse but may desensitize with prolonged use. Commonly cycled on and off.
Recombinant human growth hormone. Used for GH deficiency, anti-aging, and body composition optimization. Requires careful dosing and monitoring via bloodwork.
Long-acting analog of insulin-like growth factor 1 with extended half-life. Promotes muscle growth, recovery, and cellular repair. More potent than native IGF-1.